| Frequent optical imaging during breast cancer neoadjuvant chemotherapy reveals dynamic tumor physiology in an individual patient. | |
| | |
MedLine Citation:
|
PMID: 20542448 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
RATIONALE AND OBJECTIVES: Imaging tumor response to neoadjuvant chemotherapy in vivo offers unique opportunities for patient care and clinical decision-making. Detailed imaging studies may allow oncologists to optimize therapeutic drug type and dose based on individual patient response. Most radiologic methods are used sparingly because of cost; thus, important functional information about tumor response dynamics may be missed. In addition, current clinical standards are based on determining tumor size changes; thus, standard anatomic imaging may be insensitive to early or frequent biochemical responses. Because optical methods provide functional imaging end points, our objective is to develop a low-barrier-to-access bedside approach that can be used for frequent, functional assessment of dynamic tumor physiology in individual patients. MATERIALS AND METHODS: Diffuse Optical Spectroscopic Imaging (DOSI) is a noninvasive, bedside functional imaging technique that quantifies the concentration and molecular state of tissue hemoglobin, water, and lipid. Pilot clinical studies have shown that DOSI may be a useful tool for quantifying neoadjuvant chemotherapy response, typically by comparing the degree of change in tumor water and deoxy-hemoglobin concentration before and after therapy. Patient responses at 1 week and mid-therapy have been used to predict clinical outcome. In this report, we assess the potential value of frequent DOSI monitoring by performing measurements on 19 different days in a 51-year-old subject with infiltrating ductal carcinoma (initial tumor size 60 x 27 mm) who received neoadjuvant chemotherapy (anthracyclines and bevacizumab) over an 18-week period. RESULTS: A composite index, the Tissue Optical Index (TOI), showed a significant ( approximately 50%) decrease over the nearly 18 weeks of chemotherapy. Tumor response was sensitive to the type of chemotherapy agent, and functional indices fluctuated in a manner consistent with dynamic tumor physiology. Final pathology revealed 4 mm of residual disease, which was detectible by DOSI at the conclusion of chemotherapy before surgery. CONCLUSION: This case study suggests that DOSI may be a bedside-capable tool for frequent longitudinal monitoring of therapeutic functional response to neoadjuvant chemotherapy. |
| | |
Authors:
|
Albert E Cerussi; Vaya W Tanamai; Rita S Mehta; David Hsiang; John Butler; Bruce J Tromberg |
Related Documents
:
|
17354908 - Extrapolating tumor invasion margins for physiologically determined radiotherapy regions. 11500138 - Enhancement of tumor oxygenation and radiation response by the allosteric effector of h... 22255918 - Design of a new probe for tumor treatment in the alternate thermal system based on nume... 6284348 - Nmr relaxation times of water protons in human colon cancer cell lines and clones. 2196118 - Expression of hepatocyte and oval cell antigens in hepatocellular carcinomas produced b... 16820868 - Vascular basement membrane-derived multifunctional peptide, a novel inhibitor of angiog... |
Publication Detail:
|
Type: Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2010-06-12 |
Journal Detail:
|
Title: Academic radiology Volume: 17 ISSN: 1878-4046 ISO Abbreviation: Acad Radiol Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-07-05 Completed Date: 2010-08-04 Revised Date: 2011-09-26 |
Medline Journal Info:
|
Nlm Unique ID: 9440159 Medline TA: Acad Radiol Country: United States |
Other Details:
|
Languages: eng Pagination: 1031-9 Citation Subset: IM |
Copyright Information:
|
2010 AUR. Published by Elsevier Inc. All rights reserved. |
Affiliation:
|
Beckman Laser Institute, University of California, Irvine, 92612, USA. acerussi@uci.edu <acerussi@uci.edu> |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiogenesis Inhibitors
/
therapeutic use Antibodies, Monoclonal / therapeutic use Breast Neoplasms / diagnosis*, drug therapy Carcinoma, Ductal, Breast / diagnosis*, drug therapy Chemotherapy, Adjuvant Diagnosis, Computer-Assisted Female Humans Middle Aged Neoadjuvant Therapy* Spectroscopy, Near-Infrared* |
| Grant Support | |
ID/Acronym/Agency:
|
2P30CA62203/CA/NCI NIH HHS; P41 RR001192-26/RR/NCRR NIH HHS; P41 RR001192-27/RR/NCRR NIH HHS; P41 RR001192-28/RR/NCRR NIH HHS; P41 RR001192-29/RR/NCRR NIH HHS; P41 RR001192-30/RR/NCRR NIH HHS; P41 RR001192-305021/RR/NCRR NIH HHS; P41 RR001192-31/RR/NCRR NIH HHS; P41-RR01192/RR/NCRR NIH HHS; R01 CA142989-01/CA/NCI NIH HHS; R01 CA142989-02/CA/NCI NIH HHS; U54 CA105480-01/CA/NCI NIH HHS; U54 CA105480-02/CA/NCI NIH HHS; U54 CA105480-03/CA/NCI NIH HHS; U54 CA105480-04/CA/NCI NIH HHS; U54 CA105480-05/CA/NCI NIH HHS; U54 CA136400-01/CA/NCI NIH HHS; U54-CA105480/CA/NCI NIH HHS; U54CA136400/CA/NCI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal; 0/bevacizumab |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A comparison of characteristics and resource use between in-hospital and admitted patients with stro...
Next Document: Lung growth in infants and toddlers assessed by multi-slice computed tomography.